Pune, India, August 2022, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Denture Adhesive Market.
The Denture Adhesive Market is expected to reach USD 2,424.3 Million by 2030 at 6.1% CAGR during the forecast period 2022-2030.
The soaring awareness regarding aesthetics, coupled with the rising demand for denture adhesives, the market is likely to flourish over the review period. High focus on dental health and rising demand for various dental procedures are likely to influence the denture adhesive market’s growth. Rising disposable income, coupled with increasing patient population, are further leading to the growth of the market. Rising adoption of advanced dental care treatments like periodontal diseases and cosmetic dentistry, especially among the geriatric population is considered to drive the market growth in the coming years.
On the contrary, high treatment cost of denture adhesive and lower dental hygiene are some of the major concerns likely to restrict the market growth in the foreseeable future.
Global Denture Adhesive Market: Segmental Analysis
The denture adhesive market has been segmented on the basis of the type of ingredients, product, etching technique, application, and end-user.
By product, the market is segmented into adhesive pads, cream, and others.
By type of ingredients, the market is segmented into anti-microbial agents, adhesive agents, flavoring agents, plasticizing agents, and others.
By etching technique, the market is segregated into self-etch, total-etch, and selective etch. Of these, the self-etch segment is likely to gain prominence and is driven by its capability to bond to enamel and dentin. Besides such enhanced properties, it also offers convenience.
Considering the application, the market comprises retention of radiation carriers, xerostomia in denture wearers, and maxillofacial defects.
With reference to end-user, the market is segregated into dental academic & research institutes, hospitals & clinics, and others. Of these, the hospitals & clinics segment is predicted to gain prominence owing to the soaring number of hospitals and clinics, high adoption of advanced technologies in dental treatments, surging demand for cosmetic dentistry, and increasing number of people opting for dental restorative procedures.
Geographically, the denture adhesive market spans across Europe, North America, South America, Asia Pacific, and the Middle East & Africa.
Considering the global scenario, North America leads the global market, mainly due to the soaring awareness regarding aesthetics, rising demand for several dental procedures, and high use of dentures in the region. Extensive focus on dental health and the soaring number of dental reconstructions are some of the primary growth stimulants of the regional market. The rising per capita income of the individuals in the region and increasing healthcare expenditure will also assist in the growth of the market.
The denture adhesive market in the European region is anticipated to acquire the second position and is estimated to register robust growth due to the surging demand for dental reconstruction surgeries, which is caused by road accidents. Moreover, extensive research and development on dental implants, growing funding for research and government initiatives, and the development of advanced medical treatments are estimated to propel the market growth in the coming years.
The market in the Asia Pacific will register the fastest growth owing to the rising rate of road accidents, which has further fueled the demand for dental reconstruction surgeries. The soaring awareness regarding aesthetics and high availability of favorable reimbursement policies will drive the market in the APAC.
Explore In-depth Details: Denture Adhesive Market Research Report
The top players operating in the denture adhesive market include Valeant Pharmaceuticals International, Abbott Laboratories, Janssen Biotech, Inc., Novartis AG, AbbVie, Inc., Alkem Laboratories Limited, Takeda Pharmaceutical Company Limited, UCB Inc, Pfizer Inc., Biogen Inc., and Allergan plc.